Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eloxx Pharmaceuticals : Roche Discloses 5.3% Stake in Eloxx Pharmaceuticals

06/15/2021 | 06:16am EDT


ę MT Newswires 2021
All news about ELOXX PHARMACEUTICALS, INC.
07/16ELOXX PHARMACEUTICALS : Corporate Controller, Treasurer Resigns
MT
07/16ELOXX PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-..
AQ
07/16Gary Rakers to Resign as Executive Director, Finance & Accounting, Corporate ..
CI
07/06ELOXX PHARMACEUTICALS : Provides Enrollment Update for Ongoing Phase 2 Clinical ..
PU
07/06ELOXX PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regulat..
AQ
07/06Eloxx Pharmaceuticals, Inc. Announces the departure of Neil Belloff as Chief ..
CI
07/06ELOXX PHARMACEUTICALS : Pharma Expects Part of Mid-Stage Cystic Fibrosis Trial D..
MT
07/06Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical..
GL
07/06Eloxx Pharmaceuticals, Inc. Provides Enrollment Update for Ongoing Phase 2 Cl..
CI
06/30ELOXX PHARMACEUTICALS : Mizuho Securities Starts Eloxx Pharmaceuticals at Buy Wi..
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,18x
Yield 2021 -
Capitalization 112 M 112 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 90,4%
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | ELOX | US29014R1032 | MarketScreener
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,30 $
Average target price 3,78 $
Spread / Average Target 190%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Tomer Kariv Chairman
Thomas P. Haverty Chief Medical Officer
Vijay Modur Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-67.34%112
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
IQVIA HOLDINGS INC.39.45%47 899
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-6.81%28 780